Izirize Solution for Injection contains Inclisiran 284 mg, a novel small interfering RNA (siRNA) therapeutic indicated for the treatment of hypercholesterolemia and mixed dyslipidemia. Inclisiran specifically targets the hepatic synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) by promoting the degradation of PCSK9 messenger RNA, resulting in increased low-density lipoprotein receptor (LDL-R) recycling and enhanced clearance of LDL cholesterol (LDL-C) from the bloodstream. Izirize is administered via subcutaneous injection, typically as a two-dose regimen followed by maintenance doses every six months, providing sustained LDL-C reduction. Clinical studies have demonstrated that Inclisiran significantly lowers LDL-C levels in patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lipid-lowering therapy despite maximally tolerated statins. The safety profile is generally favorable, with injection site reactions being the most common adverse events. Izirize offers a convenient dosing schedule and represents an important therapeutic option for patients at high cardiovascular risk needing effective LDL-C management. It should be used under medical supervision, with periodic monitoring of lipid levels and liver function tests to ensure efficacy and safety.